3-day azithromycin (AZM) 500 mg qd versus 10-day clarithromycin (CLA) 500 mg bid for acute exacerbation of chronic bronchitis (AECB) in adults Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002
Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
Efficacy of sequential intravenous (i.v. ) to oral (p.o. ) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to m. pneumoniae or chlamydia spp. Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
IV azithromycin (AZM)/ceftriaxone (CEF) followed by PO AZM vs IV levofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004
Comparative trial of cefuroxime 250 mg with probenecid 250 mg with cefuroxime 500 mg in lower respiratory tract infection Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002
LATE-BREAKING ABSTRACT: RESPIRE 1: Ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB) Source: International Congress 2016 – Clinical update on bronchiectasis Year: 2016
Pharmacokinetics of consecutive oral moxifloxacin 400 mg/day in patients with respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002
Descriptive study of a Legionella pneumophila pneumonia outbreak in Pamplona in June 2006 Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
3x2g ceftazidime as short infusion versus 2x2g ceftazidime as 7 hours infusion in patients with acute exacerbation of severe chronic bronchitis (AECB) Source: Eur Respir J 2001; 18: Suppl. 33, 138s Year: 2001
No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003
Prevalence of penicillin resistant pneumococci among children with community acquired pneumonia admitted in a secondary reference hospital – 5 year study Source: Eur Respir J 2006; 28: Suppl. 50, 494s Year: 2006
Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Efficacy, safety and tolerability of 3 day azithromycin versus 10-day amoxillin/clavulanic acid in the treatment of children with pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 143s Year: 2003
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004) Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006
Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
Efficacy and cost analysis of ceftriaxone 1 g versus aminopenicillin-betalactamase inhibitors in the treatment of pneumonia on general medical wards Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules Source: Eur Respir J, 54 (6) 1900580; 10.1183/13993003.00580-2019 Year: 2019